IDEXX Expands Kidney Disease Detection with SDMA Integration into Catalyst Chemistry Profiles
Event summary
- IDEXX integrates SDMA renal biomarker into Catalyst CLIPs chemistry profiles, launching in June 2026 for U.S. and Canadian markets.
- Approximately 119 million SDMA tests performed globally since 2015, primarily through reference labs and increasingly on Catalyst platform.
- SDMA recognized by IRIS as a key biomarker for evaluating kidney function in pets.
- Study in Journal of the American Veterinary Medical Association shows early CKD treatment with renal diet improves survival in cats.
The big picture
IDEXX's move to integrate SDMA into its Catalyst chemistry profiles aligns with the broader trend of early disease detection in veterinary medicine. By embedding this biomarker into commonly used diagnostic tools, IDEXX aims to streamline workflows for veterinarians while potentially expanding its market reach. The strategic shift underscores the company's focus on scaling clinically relevant diagnostics through existing platforms, positioning it to capture a larger share of the growing pet healthcare market.
What we're watching
- Adoption Pace
- How quickly veterinarians will integrate SDMA into routine diagnostics and whether this drives increased Catalyst platform usage.
- Clinical Impact
- Whether earlier detection of kidney disease through SDMA will translate into measurable improvements in pet health outcomes.
- Revenue Growth
- The pace at which this integration contributes to IDEXX's long-term revenue growth, particularly in the veterinary diagnostics segment.
Related topics